KIF18A
41 programs · 41 companies
Programs
41
Companies
41
Active Trials
39
Targeting KIF18A
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| Niranesiran | Johnson & Johnson | Phase 2 | Wet AMDNSCLC | |
| Riluinavolisib | Moderna | NDA/BLA | MMPSP | |
| NUV-2032 | Nuvalent | Preclinical | ET | |
| DNL-9555 | Denali | Phase 1/2 | EoEFabry | |
| Lisoosocimab | Zealand Pharma | Approved | EoE | |
| Talatenlimab | Praxis Precision | Phase 1/2 | MCC | |
| Talainavolisib | Fate Ther | Approved | ACCADPKD | |
| SLD-2973 | Solid Bio | NDA/BLA | Endometrial CaPsoriasis | |
| UCB-7877 | UCB | NDA/BLA | SMANMOSD | |
| Gelirelsin | Simcere | Phase 2 | AsthmaRett | |
| CHI-IIT-962 | Children's Oncology Grp | Preclinical | Bladder Ca | |
| SEO-IIT-678 | Seoul Natl Univ Hosp | Phase 2 | RA | |
| Miritinib | Tome Bio | Approved | PAHBladder Ca | |
| Motarasimod | Enanta | Phase 1 | IPFMG | |
| Polazasiran | Morphic Ther (Lilly) | Phase 3 | FSGSAngelman | |
| SNG-5665 | Soligenix | Phase 2/3 | RB | |
| Capitapinarof | Galena Biopharma | Preclinical | Cholangiocarcinoma | |
| Kematinib | Sonnet Bio | Approved | Cholangiocarcinoma | |
| Sovafotisoran | Guardant Health | Phase 1 | CFCeliac | |
| SPA-2229 | Spark (Roche) | Phase 1 | CTCLRA | |
| Motafutibatinib | Oncorus (sold) | Approved | MesoGBM | |
| PMV-7390 | PMV Pharma | Phase 2 | Atopic DermSCLC | |
| Talarelsin | Ocugen | Phase 3 | Rett | |
| Geliderotide | Abcam (Danaher) | Phase 3 | MG | |
| Polarasimod | DBV Technologies | Approved | MGWet AMD | |
| Tirazumab | Plurilock | Phase 2/3 | ADPKDAngelman | |
| GRF-1969 | Grifols SA | Phase 1/2 | T2D | |
| BAY-8160 | Bayer AG | Phase 1/2 | GBMSMA | |
| BCA-2794 | Biocartis | Approved | PV | |
| Tezetinib | Ajanta Pharma | Phase 1 | Gastric Ca | |
| SIA-1629 | Siam Bioscience | Phase 2/3 | FLCSU | |
| Rimalucimab | Teva Pharma | Phase 2/3 | CholangiocarcinomaSCD | |
| NAT-IIT-130 | Natl Cancer Ctr Singapore | Phase 1 | CTCL | |
| SIR-IIT-176 | Siriraj Hospital | Preclinical | IgAN | |
| FRO-509 | Frontline BioSciences | Approved | FLCKD | |
| KRK-8556 | KRKA | Phase 1 | PBCRett | |
| Rilulemzoparlimab | Cipher Pharma | Approved | Cholangiocarcinoma | |
| CRD-4273 | Cardiol Therapeutics | Phase 1/2 | Psoriasis | |
| AMY-7629 | Amyris | Phase 2/3 | PompeHeart Failure | |
| Olpabrutinib | Quanterix | Phase 1/2 | HCCFL | |
| Cevivorutinib | MedPacto | Phase 2/3 | Hemophilia ACLL |